BioMimetic Therapeutics, Inc. BMTI announced today that it has
submitted to the Food and Drug Administration (FDA) an amendment to its
Pre-Market Approval (PMA) application for Augment^® Bone Graft for its use as
an alternative to autograft in hindfoot and ankle fusion procedures. The
amendment provides supplemental information requested by the FDA in a
post-panel response letter announced by the Company earlier this year.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in